Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Etoricoxib
Drug ID BADD_D00856
Description Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.
Indications and Usage For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
Marketing Status approved; investigational
ATC Code M01AH05
DrugBank ID DB01628
KEGG ID D03710
MeSH ID D000077613
PubChem ID 123619
TTD Drug ID D09MGR
NDC Product Code 42765-006; 68554-0053
UNII WRX4NFY03R
Synonyms Etoricoxib | MK 0663 | MK-0663 | MK0663 | Arcoxia | L-791456 | L 791456 | L791456
Chemical Information
Molecular Formula C18H15ClN2O2S
CAS Registry Number 202409-33-4
SMILES CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinusitis11.01.13.005; 22.07.03.007--
Sjogren's syndrome06.08.02.011; 07.06.01.010; 10.04.04.009; 15.06.01.015---
Skin disorder23.03.03.007---
Skin infection11.01.12.003; 23.11.04.007--
Skin ulcer23.07.03.003; 24.04.03.007--
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Stomatitis07.05.06.005--
Sunburn12.05.02.001; 23.03.09.007---
Tendonitis12.01.07.007; 15.07.01.003---
Tenosynovitis15.07.01.004---
Thirst08.01.09.021; 14.03.02.007---
Thrombocytopenia01.08.01.002---
Tinea pedis11.03.08.004; 23.11.03.012---
Tinnitus04.04.01.002; 17.04.07.004--
Tongue disorder07.14.01.002---
Tongue oedema07.14.02.007; 10.01.05.008; 23.04.01.009---
Toothache07.09.06.001--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Transient ischaemic attack17.08.04.001; 24.04.06.005--
Traumatic arthropathy12.04.03.006; 15.01.01.013---
Tremor17.01.06.002--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002---
Urinary tract disorder20.08.01.001---
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection11.01.10.002; 21.14.02.002--
Vision blurred06.02.06.007; 17.17.01.010--
The 6th Page    First    Pre   6 7 8    Next   Last    Total 8 Pages